<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973634</url>
  </required_header>
  <id_info>
    <org_study_id>2012/655</org_study_id>
    <nct_id>NCT01973634</nct_id>
  </id_info>
  <brief_title>Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery.</brief_title>
  <acronym>SeqB vs SIB</acronym>
  <official_title>Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whole breast irradiation (WBI) after breast conserving surgery for early-stage breast cancer
      halves the recurrence risk and reduces the breast cancer death by about one sixth. A
      sequential boost (SeqB) dose to the tumour bed further improves local control, but also
      increases the risk of late skin toxicity and cosmetic changes. At Ghent University Hospital
      WBI is prescribed in 15 fractions of 2.67 Gy according to the START-B hypofractionation
      scheme. A sequential boost is typically given in 4 to 8 extra fractions which prolongs the
      overall treatment time. The boost dose can also be delivered within the 15 fractions of WBI,
      the so-called simultaneous integrated boost (SIB). SIB shortens the overall treatment time
      which is convenient for the patient and the radiotherapy department. In this study we wish to
      test the hypothesis of acceptable skin toxicity and reduced cost with SIB using
      hypofractionated prone intensity modulation radiotherapy IMRT with topographical dose
      painting, a technique recently developed in our group. Patients are randomized between SeqB
      and SIB.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of acute moist desquamation during or in the first 2 weeks after radiotherapy.</measure>
    <time_frame>weekly during radiotherapy, 2 weeks after the end of radiotherapy.</time_frame>
    <description>Clinical inspection of the treated breast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of acute skin toxicity.</measure>
    <time_frame>Weekly during radiotherapy and 2 weeks after the end of radiotherapy.</time_frame>
    <description>Clinical inspection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of chronic skin toxicity and cosmesis after radiotherapy.</measure>
    <time_frame>2 weeks, 1 year, 2 years and 5 years after radiotherapy.</time_frame>
    <description>Inspection, clinical evaluation, digital photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after radiotherapy.</measure>
    <time_frame>2 weeks, 1 year, 2 years and 5 years after radiotherapy.</time_frame>
    <description>QLQ C30 and QLQ BR23 quality of life questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis.</measure>
    <time_frame>Blood sample within 1 week before the start of radiotherapy</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of costs for the patient for the full treatment.</measure>
    <time_frame>Over the period of radiotherapy treatment, with a maximum of 5 weeks.</time_frame>
    <description>Activity based costing models.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Early Breast Cancer Patients Needing Radiotherapy After Breast Conserving Surgery.</condition>
  <arm_group>
    <arm_group_label>Minimal surgical margin 1 mm, conventional arm: seq boost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal surgical margin of 1 mm, experimental arm with SIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal surgical margin &lt;1 mm, conventional arm: seq boost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimal surgical margin &lt; 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal surgical margin &lt; 1 mm, experimental arm with SIB.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimal surgical margin &lt; 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)</intervention_name>
    <description>Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)</description>
    <arm_group_label>Minimal surgical margin 1 mm, conventional arm: seq boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)</intervention_name>
    <description>Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)</description>
    <arm_group_label>Minimal surgical margin of 1 mm, experimental arm with SIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)</intervention_name>
    <description>Minimal surgical margin &lt; 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)</description>
    <arm_group_label>Minimal surgical margin &lt;1 mm, conventional arm: seq boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)</intervention_name>
    <description>Minimal surgical margin &lt; 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)</description>
    <arm_group_label>Minimal surgical margin &lt; 1 mm, experimental arm with SIB.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Female patients AND breast conserving surgery AND multidisciplinary decision of adjuvant
        WBI with a boost to the tumor bed AND age â‰¥ 18 years AND informed consent obtained, signed
        and dated before specific protocol procedures

        Exclusion criteria

          -  Mastectomy

          -  Need for lymph node irradiation

          -  No boost

          -  Bilateral breast irradiation

          -  Patient not able to reach or maintain the prone position

          -  Pregnant or breastfeeding

          -  Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study

          -  Patient unlikely to comply with the protocol; i.e. uncooperative attitude, inability
             to return for follow-up visits, and unlikely to complete the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Neve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liv Veldeman, MD, PhD</last_name>
    <email>Liv.Veldeman@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liv Veldeman, MD, PhD</last_name>
      <email>Liv.Veldeman@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Liv Veldeman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wilfried De Neve, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

